First person don receive experimental vaccine as part of clinical trial to test vaccines against Bundibugyo strain of Ebola for Democratic Republic of Congo.
First Person Don Receive Experimental Ebola Vaccine for Trial Against Rare Strain
Doctors Without Borders don announce say dem don give the first person experimental vaccine as part of clinical trial to test vaccines against Bundibugyo strain of Ebola for Democratic Republic of Congo (DRC).
The trial, wey dem call Tumaini, go check how safe the vaccine candidates be, how dem dey help the body fight the virus, and how well dem fit protect people against the disease.
According to World Health Organization’s Regional Office for Africa, the outbreak don cause more than 10,000 cases and nearly 5,000 deaths. As e be now, no approved vaccine or treatment dey specifically for Bundibugyo strain.
The trial dey led by DRC National Institute for Biomedical Research and University of Antwerp Global Health Institute for Belgium, with support from local and international health organisations.
People wey get contact with person wey dem recently confirm say e get the virus within the last 21 days fit take part for the trial. Researchers go compare different vaccine candidates and treatment options to see how well dem work.
The first vaccine candidate wey dem dey test na ERVEBO, wey get approval to protect against Zaire strain of Ebola, no be Bundibugyo strain.
Researchers go also study vaccines wey Moderna and University of Oxford dey develop specifically against Bundibugyo, together with Serum Institute of India.
The trial go include children and pregnant women because dem fit dey among the people wey the outbreak affect. An independent committee go monitor the results as the trial dey continue, to help guide vaccine use for future outbreaks.
Comments
Add a comment